BrainCool and The R Adams Cowley Shock Trauma Center (“Shock Trauma”) at University of Maryland have received a grant of USD 100,000 for the project “IQool Fever Prevention in the Neuro-ICU”

The US temperature management market is divided into two patient types, cardiac care and neurocritical care.

Shock Trauma, one of the largest trauma centers in the US is currently evaluating the IQool™ System for purchase for the patient type neurocritical care. IQool™ has several unique features using an intelligent, safe and simple method.

In addition, two other major trauma centers on the east coast are currently evaluating IQool™, and BrainCool will host a satellite symposium in New York City in April, where data of the device is to be presented.

Aside from the above sales target projects, BrainCool and Schock Trauma have applied for non-dilutive grants, one of which has now been approved. The objective of the grant, which will run through 2020, is to promote the commercialization of advanced technology (IQool™ System) through a university/industry partnership, and to strengthen the economy of the state of Maryland, where BrainCool’s US subsidiary is located. 

The project will be led by Professor Dr. Neeraj Badjatia, author of the guidelines from the US Neurocritical Care Society (NCS) for temperature management of fever in patients with acute brain injury. The project could be a multiyear project as the project will be eligible for follow-on funding in twelve months, subject to an evaluation of the results of the first year's research, the company’s business progress, and submittal of a phase II proposal.

The grant project will be focusing on a further developed model for treatment of fever and evaluate two patented products developed with the EU project BrainSave, a brain temp sensor and a micro shivering detector.

BrainCool’s CEO Martin Waleij comments;

• The neuro temperature management market is in high growth in the US and the project manifests the objective of BrainCool becoming the market leader in temperature management in the US over the coming years. Furthermore, it serves as a facilitator of creating evidence of the products and projects that have been developed within our EU grant, BrainSave, and this with the major KOL in neurocritical care in the US.

Neurogenic fever has been shown to be related to extended hospital stays in neurologically injured patients. Fever is present in nearly 70% of acute brain injury (ABI) patients admitted to a neuro-intensive care unit (NICU) and is associated with poor outcome.

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.